Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Review

An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges

Xiaoying Xu \textsuperscript{a,b,*,1}, Yuheng Chen \textsuperscript{c,1}, Xinyu Lu \textsuperscript{b,1}, Wanlin Zhang \textsuperscript{b}, Wenxiu Fang \textsuperscript{b}, Luping Yuan \textsuperscript{b}, Xiaoyan Wang \textsuperscript{b,*,1}

\textsuperscript{a} School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
\textsuperscript{b} School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311402, China
\textsuperscript{c} The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310053, China

\textbf{ARTICLE INFO}

\textbf{Keywords:}
COVID-19
SARS-CoV-2
Antiviral
RdRp
Inhibitors

\textbf{ABSTRACT}

The highly transmissible variants of SARS-CoV-2, the causative pathogen of the COVID-19 pandemic, bring new waves of infection worldwide. Identification of effective therapeutic drugs to combat the COVID-19 pandemic is an urgent global need. RNA-dependent RNA polymerase (RdRp), an essential enzyme for viral RNA replication, is the most promising target for antiviral drug research since it has no counterpart in human cells and shows the highest conservation across coronaviruses. This review summarizes recent progress in studies of RdRp inhibitors, focusing on interactions between these inhibitors and the enzyme complex, based on structural analysis, and their effectiveness. In addition, we propose new possible strategies to address the shortcomings of current inhibitors, which may guide the development of novel efficient inhibitors to combat COVID-19.

\section{Introduction}

At the end of 2019, a severe acute respiratory syndrome caused by a novel coronavirus (SARS-CoV-2) initially emerged in China and later spread rapidly around the world, causing a global pandemic COVID-19 [1]. As of September 2022, the World Health Organization (WHO) had recorded more than 611 million confirmed cases of COVID-19 globally and more than 6 million related deaths (https://covid19.who.int/).

SARS-CoV-2, the causative pathogen of COVID-19, is a member of betacoronavirus genus of the Coronaviridae family, which possesses a single-stranded, positive-sense RNA that shares \~96\% sequence identity with bat-origin RaTG13 CoV and \~80\% sequence identity with SARS-CoV. The 30-kb genome of this novel coronavirus contains 14 open reading frames (ORFs) that encode at least 27 proteins. The 3' end of the genome encodes four typical structural proteins of coronaviruses, namely, spike (S), envelope (E), membrane (M), and nucleocapsid (N) protein, as well as eight accessory proteins, which have roles in viral pathogenesis and host immunity suppression. After being primed by the host serine protease TMRPSS2, the virus can enter host cells via attachment of its spike protein with the host cell angiotensin converting enzyme II (ACE2) receptor [2,3]. In addition, the two leading open reading frames at the 5' end, ORF 1a and ORF 1b, express two replication polyproteins, namely pp1a and pp1ab, which are further hydrolyzed into 16 nonstructural proteins (nsp1-16) [4]. Among those, nsp12, also known as RNA-dependent RNA polymerase (RdRp), is involved in directing viral genome replication and transcription [5] (Fig. 1).

Different variants of SARS-CoV-2 are continually emerging, bringing new waves of infection worldwide. Following the D614G, Beta/Gamma, and Delta variants of concern (VOC), the Omicron variant is responsible for the largest wave pandemic at present [6]. All of these new variants contain mutations in the spike protein and are characterized by enhanced transmissibility or virulence, decreased sensitivity to current

\textbf{Abbreviations:} C-RTC, central replication-transcription complex; DENV, dengue virus; dpi, days post-infection; E-RTC, elongation replication-transcription complex; FDA, Food and Drug Administration; FFV, favipiravir; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HIV, Human Immunodeficiency virus; IMPDH, inosine monophosphate dehydrogenase; MP, monophosphate; NALs, nucleoside analog inhibitors; NH, β-D-N4-hydroxycytidine; NiRAN, nidovirus RdRp-associated nucleotidyltransferase; NNIs, non-nucleoside inhibitors; nsp, nonstructural protein; NTP, nucleoside triphosphate; ORF, open reading frame; RBV, ribavirin; RdRp, RNA-dependent RNA polymerase; RTC, replication-transcription complex; RDV, remdesivir; SOF, sofosbuvir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; UMP, uridine monophosphate; VOC, variant of concern; ZIKV, Zika virus.

\* Corresponding authors.

\textbf{E-mail addresses:} 20181005@zcmu.edu.cn (X. Xu), xy.wang@zcmu.edu.cn (X. Wang).

\* These authors contributed equally to this work.

https://doi.org/10.1016/j.bcp.2022.115279

Received 7 August 2022; Received in revised form 27 September 2022; Accepted 27 September 2022

Available online 6 October 2022

0006-2952/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
vaccines or neutralizing monoclonal antibodies (mAbs), and the ability to evade detection [7]. Given the concern over the immune escape by the variants of current vaccines, developing broad-spectrum and effective drugs against SARS-CoV-2 and its variants remains a priority strategy for treatment and prevention.

RdRp, a critical enzyme in the viral life cycle, is a prime target for developing effective antivirals against SARS-CoV-2 and many variants, because it is the most conserved protein across coronaviruses and lacks a human homolog. Therefore, we summarize the recent advances in the structural understanding of SARS-CoV-2 RdRp and the interaction mechanisms and effects of inhibitors targeting it, to help guide future research and drug discovery.

2. Function and structure of SARS-CoV-2 RdRp

After entry into the host cells, SARS-CoV-2 employs a so-called replication and transcription complex (RTC), assembled by nonstructural proteins, to synthesize the negative-strand template, the positive-strand genomic RNA and subgenomic mRNAs of virus [8]. The central component of the RTC is the highly conserved catalytic subunit nsp12 (RdRp), which is responsible for the synthesis of viral RNA. However, nsp12 alone displays extremely low enzymatic activity and needs to be stimulated with two accessory proteins (nsp7 and nsp8). Thus, the nsp12-nsp7-nsp8 subcomplex (known as holoenzyme RdRp, holo-RdRp) is defined as the minimal core component for mediating the synthesis of coronavirus RNA [9].

The structures of nsp12 in complex with template-primer RNA (central RTC, C-RTC), a mini RTC composed of helicase (nsp13) and C-RTC for the elongation of nucleic acid (elongation RTC, E-RTC), and an extended E-RTC composed of a single RNA-binding protein (nsp9) have been determined [8,10] (Fig. 2A). Structural information about the SARS-CoV-2 core polymerase complex (nsp12-nsp7-nsp8) suggests that the nsp12 subunit contains an N-terminal NiRAN domain, an interface domain, a C-terminal RdRp domain, and a previously undefined β-hairpin motif. Among these, the RdRp domain adopts a typical right-hand configuration, composed of the palm, finger, and thumb subdomains, to form a catalytic chamber, in which the template-directed RNA synthesis takes place [11]. Within the core RdRp domain, the active site is subdivided into seven conserved motifs (A–G), mediating template-directed RNA synthesis [12]. The nsp7-nsp8 heterodimer binds the thumb subdomain of RdRp, and the second nsp8 (nsp8-2) subunit clamps the top region of the finger subdomain of RdRp, forming additional interactions with the interface domain (Fig. 2B). The partial double-stranded template-primer RNA is embraced by the palm-finger-thumb subdomains, and two nsp8 molecules promote the polymerase activity by stabilizing existing RNA through the interactions between positively charged residues of their long N-terminal helical extensions and the RNA backbone (Fig. 2C). Two nsp13 protomers, namely nsp13_F (fingers) and nsp13_T (thumb), bind to the plane region formed by the nsp12 and two nsp8 protomers (Fig. 2D). The conformation of nsp13_T is conserved, which stabilizes the architecture of RTC. However, nsp13_F, which channels the unpaired 5′ extension of the RNA template to the RdRp active site in E-RTC, moves down to the template-primer RNA clamped by nsp8-1 and nsp8-2 upon nsp9 binding, to facilitate the viral mRNA synthesis (Fig. 2E). The NiRAN domain of nsp12 at the back side of RdRp, which is absent in RNA viruses outside the order Nidovirales, possesses guanylyltransferase activity, catalyzing the formation of the cap core structure (GpppA). Meanwhile, nsp9 binds tightly to NiRAN, allowing the nsp9 N terminus to insert into the catalytic center of nsp12 NiRAN, which then inhibits the activity [13,14].

3. Inhibitors of RdRp

According to the structures and modes of action, inhibitors of RdRp fall into two main categories, one is nucleoside analog inhibitors acting at the substrate site, the other one is non-nucleoside inhibitors interacting with allosteric binding sites [15].

3.1. Nucleoside analog inhibitors (NAIs)

Nucleotide analogs are considered the most promising inhibitors of RdRp. NAIs are generally classified into three major classes: mutagenic...
nucleosides, obligate chain terminators and delayed chain terminators. To compete with the natural substrates of RdRp, NAIs require activation to the pharmacologically active triphosphate form (NTP) by host kinases, which lead them to be incorporated into the nascent viral RNA with the energy provided by the hydrolysis and release of the pyrophosphate group of the NTP. Once incorporated, NAIs then terminate RNA synthesis or induce mutations in progeny RNA. Since the pandemic broke out, many NAIs have been tested against SARS-CoV-2, and some structures of them have been solved to clarify their inhibition mechanisms.
3.1.1. Remdesivir

Remdesivir (RDV, formerly GS-5734) is a prodrug of a 1′-cyano-modified adenosine nucleotide analog, which was developed initially to combat Ebola virus in 2014 [16] (Fig. 3A). Nevertheless, the antiviral activity of RDV is considerably broad-spectrum and includes members of several virus families, including filoviruses (e.g., Ebola) and coronaviruses (e.g., SARS-CoV and MERS-CoV) [17,18]. Upon cellular uptake, RDV is metabolized into the adenine metabolite and further processed into the monophosphate derivative (RDV-MP) and ultimately into the active nucleoside triphosphate (RDV-TP) derivative, which is the substrate competing with ATP for incorporation by the viral RdRp, thereby resulting in inhibiting viral RNA synthesis [19].

RDV is the first candidate that has received much attention for COVID-19 therapy, demonstrating efficacy against SARS-CoV-2 and related coronaviruses both in vitro and in vivo animal models [20–22]. Apart from preclinical tests, the possible clinical use of RDV to fight against coronavirus has been supported. It reduced early-stage mortality and the need for high-flow oxygen supplementation as well as invasive mechanical ventilation among hospitalized COVID-19 patients [23]. In addition, an improvement in the primary endpoint was reported with the control, according to an interim analysis in the Adaptive COVID-19 Treatment Trial (NCT04280705) [24,25]. To date, RDV is the first and only one FDA-authorized drug to treat COVID-19 patients in such severe emergency [26].

Furthermore, the structure of the RdRp-RNA-RDV complex has been solved [11,13,27] (Fig. 3B). RDV can be efficiently incorporated and allows subsequent catalysis. As an adenosine monophosphate analog, the RDV-MP molecule is incorporated into the primer strand and forms a base-stacking interaction with two hydrogen bonds with the uridine base from the template strand. In addition, RDV-MP interacts with residues K545 and R555 in motif F, which stabilize the incoming nucleotide in the correct position for catalysis [11]. Compared with other classical chain terminators, favorable reactivity for the RDV-TP over ATP and delayed chain termination of nascent viral RNA at the i + 3 position (where i corresponds to the position of the first incorporated RDV-MP) are observed to be the crucial features of the mechanism of inhibition with SARS-CoV-2 RdRp complexes [28,29]. Structural analysis and enzymological characterization further suggested that the 1′-CN substituent of the incorporated RDV-MP will sterically clash with the side-chain of the S861 poised near the product strand backbone at the −4 position in the thumb domain of nsp12 upon further chain elongation, and probably lead to a significant distortion of the RNA position, hampering the translocation of RNA to the −4 position. Failure to translocate would arrest the RTC and lead to the termination of RNA synthesis unless the translocation impediment is repaired [27,30]. Although the delayed termination induced by RDV is evident in the meta-stable complex, a recent study reveals that RDV can overcome the S861 roadblock under certain circumstances, allowing processive RNA synthesis by passing the corresponding “i + 3”-related SARS-CoV-2 nsp12 S861 site. In that case, RDV might become part of the RNA template or affect post-transcription events [31,32]. Overall, although much has been learned about RDV for COVID-19 therapy and its possible side effects, there is still more to be learned.

![Figure 3](https://example.com/fig3.png)
3.1.2. Favipiravir

Favipiravir (FPV, T-705), a derivative of pyrazine carboxamide, was originally developed as an anti-influenza drug and is currently approved in Japan for treating influenza infection [33] (Fig. 4A). In addition to influenza, favipiravir has demonstrated antiviral activity against some other RNA viruses, including Ebola virus, flaviviruses, noroviruses, arenaviruses, foot-and-mouth disease virus, phleboviruses, hantaviruses, enteroviruses, Western equine encephalitis virus, rabies and respiratory syncytial virus [33].

In COVID-19 clinical studies, FPV showed effectiveness in controlling disease progression, and its one-week clinical recovery rate of patients with moderate COVID-19 was 71% [34,35]. After treating severe COVID-19 patients with FPV, the lymphocyte count can be improved [36]. Therefore, oral therapy with FPV has been recommended to tackle COVID-19 in several countries. For instance, in India, it is a prominent antiviral used in clinics for COVID-19 management and treatment [37].

Similar to RDV, FPV is a nucleotide analog inhibitor of RdRp. FPV (prodrug) can be metabolized in the body to be an active metabolite, namely favipiravir-ribofuranosyl-5′-triphosphate (FPV-RTP), via ribosylation and phosphorylation, which acts as a competitor to purine nucleosides. The FPV-RTP is weakly incorporated into the RNA primer strand and binds to the active site of the viral RdRp, transforming the binding pocket into a catalytically nonproductive conformation, and finally terminates replication of viral RNA at the site of incorporation [38]. FPV-RTP exerts its antiviral effect through lethal mutagenesis, where it is mis-incorporated into a nascent viral RNA by RdRp, and promiscuously paired to natural nucleotides cytosine (C) and uracil (U) (Fig. 4B). In the next cycle of RNA synthesis, the regions of the viral genome that have incorporated FPV-RTP will be prone to mutagenesis, and excess mutations will finally destroy the viruses [39–41]. In addition, FPV might be associated with slowed RNA synthesis and non-obligate chain termination.

Based on the risks of adverse reactions, including decreased red blood cell production in hematopoietic tissues, increased liver function parameters, teratogenicity and embryotoxicity to human offspring, the manufacturing, selling and clinical administration of FPV are still strictly limited, which need further exploration [42–44].

3.1.3. Molnupiravir

Molnupiravir (EIDD-2801, MK-4482) is an isopropyl ester prodrug of the ribonucleoside analog β-D-N4-hydroxycytidine (EIDD-1931 or NHC) [45] (Fig. 5A). Molnupiravir could efficiently hampered the replication of SARS-CoV-2 in human airway epithelial cell cultures and various animal-infected models [46,47]. Moreover, molnupiravir is greater than 100-fold more active against SARS-CoV-2, compared with other drugs such as favipiravir. It could be also effective in treating patients with resistance to RDV [48–50]. Other available data from a positive interim analysis in a phase III study suggested that molnupiravir significantly reduced the risk of death in patients with mild to moderate COVID-19 by 50% compared with placebo [51]. Notably, most of the subjects were infected with mutant strains, reflecting the potential effectiveness of molnupiravir against new variants [52,53]. Hence, molnupiravir was granted emergency use authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) and the FDA for COVID-19.
The antiviral mechanism of molnupiravir is similar to that of FPV. After oral administration of molnupiravir, the NHC appears rapidly in plasma, which is subsequently activated to triphosphate form in cells. After that, the NHC triphosphate is incorporated into viral RNA in place of cytosine or uracil by RdRp, causing mutations to break replication fidelity, ultimately resulting in an antiviral effect [46,48,55,56]. Structures of the complexes containing mutagenesis products illustrated that the NHC embedded in the template can form stable base pairs with either G or A in the RdRp active site, explaining how the polymerase escapes proofreading and synthesizes mutated RNA [57,58] (Fig. 5B and 5C). In particular, the cytidine base of this NHC forms an extra hydrogen bond with the guanine base from the template strand, which may explain the apparent higher potency of this NHC in inhibiting SARS-CoV-2 replication.

Nevertheless, it was reported that this NHC displays host mutational activity in an animal cell culture assay [49]. Due to the risks this suggests, it is essential to obtain a comprehensive understanding of the potential for side effects of molnupiravir through further studies.

3.1.4. Galidesivir

Galidesivir (BCX4430) is a novel synthetic adenosine analog designed as an inhibitor of RdRp (Fig. 6A). When the RdRp incorporates galidesivir triphosphate (BCX4430-TP), which prefers viral RNA polymerase rather than host polymerase, into nascent viral RNA strands, the structural change alters its electrostatic interaction, resulting in...
premature termination of the elongating RNA strand [59]. Computational modeling studies predicted that potential mechanism of galidesivir binding to SARS-CoV-2 RdRp is involves six hydrogen bonds and four hydrophobic interactions [60,61].

In vitro and in animal models, galidesivir can inhibit RNA replication of many RNA viruses, including Ebola, Zika, Marburg, yellow fever and Rift Valley fever viruses [62,63]. In SARS-CoV-2 infected Syrian golden hamster models, galidesivir reduced lung pathology when the treatment...
was initiated 24 h prior to infection, compared with untreated controls [64]. Based on these data, several clinical trials have been conducted to evaluate the efficacy of galidesivir against SARS-CoV-2.

3.1.5. Ribavirin

Discovered more than 40 years ago, ribavirin (RBV, 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) (Fig. 6B) is a guanosine analog with a broad-spectrum antiviral activity in both human cell lines and animal models [65].

RBV is converted by host kinases into RBV triphosphate (RBV-TP), which pairs with the cytidine triphosphate or uridine triphosphate in the RNA template. The ambiguous coding nature of its purine-mimicking nucleobase accounts for its antiviral effect through lethal mutagenesis [66]. In addition, RBV monophosphate is a potent inhibitor of the host inosine monophosphate dehydrogenase (IMPDH). IMPDH inhibition represses de novo synthesis of guanine nucleotides, thus affecting RNA polymerase fidelity through nucleotide pool imbalance. Alternatively, enhancing the induction of interferon-related genes is another proposed mechanism of RBV antiviral activity [67].

During the emergence of SARS-CoV-2, RBV was repurposed to treat COVID-19, and some promising results have been reported [68,69]. An observational study has indicated that RBV is well tolerated in severe patients with severe COVID-19 and may benefit them by increasing the viral clearance, resulting in a higher survival rate [70]. Furthermore, RBV was employed in a Phase II trial in combination with interferon beta-1b and lopinavir-ritonavir, to treat patients with mild to moderate COVID-19. In that trial, the combination treatment group was superior in reducing the viral load compared with lopinavir-ritonavir alone. Moreover, a hastened clinical improvement with shorter duration of hospital stays was observed in the triple combination group [71].

Despite the potential efficacy in treating COVID-19, some side effects of RBV may be of concern, primarily, hemolytic anemia. Furthermore, it cannot be prescribed to pregnant women and the elderly population because of fetal toxicity and reduction of calcium as well as magnesium levels in blood [72].

3.1.6. Sofosbuvir and daclatasvir

Sofosbuvir (GS-7977; formerly PSI-7977) (Fig. 6C) and daclatasvir (Fig. 6D) are considered safe and well-tolerated anti-HCV therapies. Sofosbuvir triphosphate competes with uridine to be incorporated by the HCV RNA polymerase (NS5B) into the elongating RNA strand, resulting in chain termination [73]. Daclatasvir inhibits HCV replication by binding to the N-terminus of nonstructural protein 5A (NS5A), affecting both viral RNA replication and virion assembly [74].

Based on the similarity of the replication mechanisms between HCV and coronavirus, it is hypothesized that sofosbuvir and daclatasvir might be potential options in the treatment of COVID-19, especially at the start of the disease and before the viral infection into the lung parenchymal cells [75]. Indeed, both sofosbuvir and daclatasvir inhibit RNA synthesis in various cell lines via different mechanisms, and co-treatment of daclatasvir/sofosbuvir shows a cooperative antiviral effect on SARS-CoV-2 replication in respiratory cells [75]. An open-label, multi-center, and randomized clinical trial was conducted on 66 adults with moderate or severe COVID-19 in Iran, which showed that the addition of sofosbuvir and daclatasvir to standard care significantly reduced the duration of hospital stay compared with standard care alone [76].

Regarding the mechanism of antiviral activity, daclatasvir favors the unfolding of SARS-CoV-2 secondary RNA structures, whereas sofosbuvir triphosphate (SOF-TP) can be incorporated by the relatively low-fidelity SARS-CoV-2 RdRp, serving as an immediate polymerase reaction terminator [77,78]. In addition, upon the incorporation of SOF-TP into RNA by the SARS-CoV-2 RdRp, sofosbuvir is removed at a lower rate by the SARS-CoV-2 exonuclease complex, relative to the natural nucleotide UMP, thus conferring a substantial level of resistance to excision [79].

Further studies are needed to confirm the efficacy, safety and mechanism of daclatasvir/sofosbuvir in combination with other drugs for prevention and treatment of COVID-19.

3.1.7. Tenofovir

Tenofovir is a broad-spectrum antiviral drug active against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection, prodrug formulations of which are tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) [80] (Fig. 6E). As a nucleotide analog, it is reported that the active triphosphate form of the tenofovir diphosphate acts as an immediate chain terminator when incorporated during the synthesis of viral DNA [80–82].

Several in silico studies show that tenofovir can bind to SARS-CoV-2 RdRp tightly, with binding energies comparable to those of native nucleotides [61]. Polymerase extension experiments in vitro demonstrated that tenofovir diphosphate was incorporated by SARS-CoV-2 RdRp, where it terminated subsequent polymerase extension, providing a molecular basis for inhibition of the SARS-CoV-2 RdRp by this nucleotide analog [77]. Emtricitabine-tenofovir, a prescription medicine approved for HIV by the U.S. FDA, was assessed in the highly susceptible SARS-CoV-2 ferret infection model. Compared with the PBS-treated control group, the emtricitabine-tenofovir-treated group showed lower viral titers in nasal washes at eight days post-infection (dpi) than the PBS-treated group. In addition, it has been reported that TDF plus emtricitabine significantly decreased the SARS-CoV-2 viral burden in recently infected COVID-19 outpatients [83].

However, only a few in vitro studies on tenofovir/TDF/TAF efficacy have been described, and the results are contradictory, which may be due to the different experimental conditions [84–86]. Further studies should proceed to better evaluate the potential efficacy of this drug (alone or in combination with other antiviral drugs) for the prevention and early treatment of COVID-19.

3.1.8. VV116

Because RDV is an intravenously administered nucleotide prodrug and is therefore inconvenient for patients, VV116 (JT001), a new orally available RDV derivative, was developed (Fig. 6F). This prodrug was endowed with significantly improved oral absorption and a favorable tissue distribution profile, circumventing the liver-targeting issue of the phosphoramidate prodrugs [87,88].

As a deuterated, tri-isobutyrate ester prodrug of the RDV parent nucleoside, VV116 is rapidly metabolized into the parent nucleoside (116-N1) in vivo. 116-N1 is intracellularly converted to the nucleoside triphosphate active form, which would interfere with the function of RdRp, thus inhibiting SARS-CoV-2 replication [89]. It has been demonstrated that VV116 showed potent activity against a panel of SARS-CoV-2 variants, including the Omicron variant [87,90]. In addition, VV116 exhibited satisfactory safety and tolerability in healthy subjects in phase I studies [89]. VV116 has been approved for the treatment of COVID-19 in Uzbekistan and is currently being investigated in phase II/III clinical trials in patients with COVID-19.

3.1.9. GS-621763

GS-621763 (Fig. 6G), which demonstrated high oral bioavailability in two relevant animal species, including non-human primates [91], is designed for optimal delivery of RDV parent nucleoside GS-441524 into the systemic circulation. Oral GS-621763 is efficiently converted to plasma metabolite GS-441524 (Fig. 6H), and in the lungs to the triphosphate metabolite identical to that generated by RDV, demonstrating a consistent mechanism of activity, with blockade of SARS-CoV-2 replication by triggering delayed chain termination of the nascent viral RNA chain and template-dependent inhibition after incorporation into viral antigenomic RNA [30,31]. Both GS-621763 and GS-441524 exhibited antiviral activity against SARS-CoV-2, including variants of concern (VOC) in lung cell lines and two different human primary lung cell culture systems that model the tissues targeted by SARS-CoV-2 in humans. Therapeutic GS-621763 administration reduced viral load and lung pathology and improved pulmonary function in a COVID-19 mouse.
When dosed therapeutically against VOC P.1 (γ) in ferrets, oral GS-621763 completely blocked virus replication and prevented transmission to untreated contact animals [93]. With confirmed in vivo efficacy, GS-621763 may become a cornerstone in the first-line defense against future pandemic threats.

3.1.10. AT-527

AT-527, an orally available prodrug of a guanosine nucleotide analog carrying a 2′-fluoro-2′C-methyl modified ribose (Fig. 7A), was shown to act as a potent broad-spectrum antiviral agent against SARS-CoV-2 [94]. After oral dosing, AT-527 is converted by cellular enzymes to the active triphosphate metabolite, AT-9010, which is structurally similar to that of sofosbuvir, with the only difference being that it has a guanine base in place of uracil [95] (Fig. 7B). AT-511, the free base of AT-527, also had potent antiviral activity when tested in vitro against several human coronaviruses, including SARS-CoV-2 [94]. AT-527 recently entered phase III clinical trials to treat COVID-19 [96].

Ashleigh Shannon et al. reported a 2.98 Å cryo-EM structure of the SARS-CoV-2 nsp12-nsp7-nsp8-RNA complex, showing AT-9010 simultaneously bound to both NiRAN and RdRp active sites of nsp12 (Fig. 7C and 7D). AT-9010 is efficiently incorporated into viral RNA, causes immediate termination of RNA synthesis, and shows resistance to excision. In addition, AT-9010 outcompetes all native nucleotides for NiRAN binding.
binding, inhibiting its nucleotidyl transferase activity. The dual mechanism of action of AT-527 should attenuate the chance of resistance mutations and represents a promising research avenue against COVID-19 [97].

3.2. Non-nucleoside inhibitors (NNIs)

Due to the proofreading activity of nsp14 exonuclease, the potential of NAIs as antiviral drugs for COVID-19 treatment may be limited [98]. An alternative route to NAIs would be the discovery of NNIs, which generally show lower resistance barriers. NNIs also have several other advantages compared with NAIs, particularly their higher chemical diversity and likely per os administration. Therefore, the discovery of non-nucleoside analog-type drugs that target SARS-CoV-2 RdRp might be particularly advantageous.

Mechanistically, most NNIs change the conformation of RdRp by binding to allosteric sites on the surface of the polymerase and then affect the binding of the catalytically active site of RdRp to the substrates [99]. Some NNIs also exert anti-inflammatory, antioxidant, immunomodulatory and cardioprotective functions, with multifunctional therapeutic benefits in the clinical management of COVID-19 [100]. Herein, we outline the most promising NNIs of SARS-CoV-2 RdRp reported so far.

3.2.1. Suramin

Suramin (Fig. 8A) is a century-old drug with a wide array of potential applications, from parasitic and viral diseases to cancer, snakebite, and autism. The antiviral activity of suramin has been known since the mid-20th century [101]. The viral inhibition mechanisms of suramin are diverse, including inhibition of viral attachment, viral entry, and release.
from host cells in part through interactions with viral capsid proteins [102,103]. It has been recently demonstrated that suramin can inhibit SARS-CoV-2 infection and decrease the viral load by 2–3 logs in cell culture by preventing cellular entry of the virus. In a primary human airway epithelial cell culture model, suramin also inhibited the progression of infection [104].

Suramin is also a potent inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase. In terms of inhibition mechanism, suramin has two independent binding sites with SARS-CoV-2 RdRp (Fig. 8B). One of the sites (suramin no. 1) is located in a cavity formed by the N-terminus of the conserved motif G and motif B, directly blocking the binding of template RNA. The other site (suramin no. 2) is located in a cavity near the catalytically active site formed by the conservative motifs A, C, E, and F, thus blocking RNA primer binding by steric hindrance [105]. This unique binding pattern is consistent with suramin and its derivatives being at least 20-fold more potent than the triphosphate form of remdesivir (RDV-TP) in polymerase activity inhibition assays in vitro. In addition, suramin, as a polyanionic compound, may bind tightly to positively charged patches of RNA-binding proteins, thereby inhibiting RNA replication [106,107]. In addition, it has been suggested that suramin, in combination with quinacrine, showed promising synergistic efficacy in inhibiting SARS-CoV-2 3CLpro [108]. These results support that suramin is an attractive drug candidate to combat SARS-CoV-2 infections by targeting multiple critical proteins in the viral life cycle.

However, suramin is also associated with unwanted side effects. The most frequent adverse reactions of suramin are nausea and vomiting for
the treatment of onchocerciasis [109]. Clinical trials in cancer patients and HIV-infected patients treated with suramin documented other toxic effects such as proteinuria, liver toxicity, corneal damage, and adrenal insufficiency [110,111]. As such, well-designed, properly controlled randomized trials and safety studies are essential for determining the feasibility of using suramin to treat COVID-19. Suramin analogs can also be developed to improve the potency and efficacy of the drug, as well as reduce its toxicity.

3.2.2. Quinoline derivatives

Quinoline, an important heterocyclic compound, is a scaffold used in the discovery of many new drug candidates [112]. It has low toxicity to humans on oral absorption and inhalation, with a logP value of 2.04 [113,114]. Quinoline derivatives have a wide range of biological properties such as antibacterial, antifungal, anti-cancer, and antiviral activities [115–117].

Three quinoline derivatives (I-13e, I-13 h, and I-13i) (Fig. 9A), which are previously reported to have significant activity against the influenza A virus RdRp, exhibit remarkable potency in inhibiting RNA synthesis by targeting SARS-CoV-2 RdRp and relatively low cytotoxicity in a cell-based assay, with therapeutic index (TI) (CC50/EC50) values of 65, 34, and 20, respectively [118]. Among these three compounds, I-13e showed the most potent inhibition of RNA synthesis and bypasses viral exonuclease activity concerns common with nucleotide inhibitors, thus holding the potential of being a drug candidate for the treatment of SARS-CoV-2. In addition, based on the activity assay, the C-2 group of the quinoline is crucial for antiviral activity, indicating that future work may focus on the modification of C-2 by introducing some large hydrophobic/hydrophilic groups [118].

3.2.3. Corilagin

Corilagin (RAI-S-37) (Fig. 9B), a gallotannin, is one of the primary active components of many traditional herbal plants. In the past few decades, corilagin was reported to exhibit anti-tumor, anti-inflammatory, and hepatoprotective activities [119].

Recently, it has been demonstrated that corilagin can effectively inhibit the polymerase activity in both cell-free and cell-based assays and potently inhibit SARS-CoV-2 infection. As expected, as a non-nucleoside inhibitor, corilagin fully resists the proofreading activity of SARS-CoV-2 nsp10-nsp14 exoribonuclease complex. Computational modeling predicts that corilagin binds to the paldo domain of RdRp and prevents conformational changes required for nucleotide incorporation by RdRp. Importantly, the combination of corilagin with RDV exhibits additive activity against SARS-CoV-2 RdRp [120]. Specifically, corilagin did not show any toxicity in acute and sub-chronic toxicity studies. After oral administration of corilagin at higher dosages, no undesirable behavioral changes or weight loss were observed in mouse models, demonstrating that corilagin was well tolerated in vivo [121,122]. These results suggest that corilagin holds promise of becoming an effective SARS-CoV-2 therapeutic.

3.2.4. Lycorine

Lycorine (Fig. 9C), a natural alkaloid extracted from the amarylidaeaceae plant lycoris radiata, also a traditional Chinese medicinal herb, exhibits multiple pharmacological activities, including regulation of autophagy and the induction of cancer cell apoptosis, and has anti-inflammatory, anti-fungal, anti-malarial, anti-tumor and antiviral activity [123]. Lycorine was previously identified as a coronavirus inhibitor according to its potent inhibition of replication in diverse coronavirus, including SARS-CoV, HCoV-OC43, HCoV-NL63, MERS-CoV, and MHV-A59 in vitro [124,125].

Lycorine exhibited dose-dependent inhibition of SARS-CoV-2 infection with a low nanomolar EC50 in infected cells without apparent cytotoxicity [126,127]. A docking simulation showed that lycorine could interact with SARS-CoV-2 RdRp through three hydrogen bonds, and the predicted binding affinity of lycorine (-6.2 kcal/mol) was higher than that of RDV (-4.7 kcal/mol). In addition, lycorine directly inhibited MERS-CoV RdRp activity, and the inhibitory effect of lycorine on MERS-CoV RdRp activity was comparable with that of RDV. These results suggest that lycorine is a potent non-nucleoside direct-acting antiviral against emerging coronavirus infections and acts by inhibiting viral RdRp activity. Therefore, lycorine may be a candidate against the current COVID-19 pandemic [128].

3.2.5. Baicalein and baicalin

Baicalein and baicalin (Fig. 9D and 9E), the major bioactive phenolic flavonoid compounds extracted from the root of Scutellaria baicalensis Georgi (called Huang-Qin), are widely used in traditional Chinese medicine for the clinical treatment of hyperlipidemia, hypertension, atherosclerosis, dysentery, and inflammatory diseases [129]. After oral administration, baicalin is metabolized into baicalein in the intestine, and baicalein exerts a broad-spectrum antiviral effect, including against influenza virus, Zika virus (ZIKV), and dengue virus (DENV) [130–132]. Clinical laboratory assessments showed that single oral doses of 100–2800 mg of baicalin were safe and well tolerated by healthy subjects, and no serious accumulation of baicalein was observed in the multiple-dose (200–800 mg) study [133,134].

Baicalein and baicalin are promising therapeutic candidates for COVID-19, exhibiting dose-dependent inhibitory effects against SARS-CoV-2 in Vero cells and Calu3 human lung cells, and baicalein is more potent compared to baicalin [135,136]. In addition, baicalein inhibited the loss of body weight, reduced viral load, and relieved lung injury in mice infected with SARS-CoV-2 [137]. Further research showed that both compounds act as SARS-CoV-2 RdRp inhibitors, directly inhibiting the activity of the SARS-CoV-2 RdRp, which could give advantages to these two compounds as non-nucleoside analog SARS-CoV-2 RdRp inhibitors [138].

4. Discussion and perspectives

Following SARS-CoV in 2003 and MERS-CoV in 2012, SARS-CoV-2 is the third coronavirus that crossed the species barrier to cause severe diseases in humans in only 20 years, implying coronaviruses may pose further threats to human health in the future. On Nov. 25, 2021, about 23 months since the first reported case of COVID-19, a new SARS-CoV-2 variant of concern, Omicron, was reported and has split into a number of sub-lineages now. The Omicron variant hosted an unprecedented number of mutations in its spike gene, which reduced vaccine effectiveness, leading to an increased incidence of reinfections and breakthrough infections [139–142]. It is a plausible strategy to develop broad-spectrum antivirals, together with vaccination programs to curb future transmissions.

In the life cycle of coronaviruses, RdRp is the prime broad-spectrum drug target due to its essential role in viral RNA synthesis, the lack of a host homolog, and high sequence and structural conservation among coronaviruses. Great efforts have been devoted to structural and functional studies of the RTC of SARS-CoV-2, to promote antiviral development against COVID-19 and other coronavirus-associated diseases. In this paper, all of the current knowledge on the inhibitors targeting RdRp of SARS-CoV-2, including nucleoside analog inhibitors and non-nucleoside inhibitors, is summarized.

It is clear that the most promising, broad-spectrum class of viral RdRp inhibitors is nucleoside analogs. However, NAs are hindered by the proofreading activity of SARS-CoV-2 nsp14 exoribonuclease, which can excise erroneous mutagenic nucleotides incorporated by RdRp into the nascent viral RNA, thus augmenting the resistance of SARS-CoV-2 RdRp to NAs [98,143]. Therefore, to potentially inhibit SARS-CoV-2 replication, nsp14 exoribonuclease needs to be included in the screening assay for RdRp NAs, and well-developed NAs should be designed to either be less recognized by the exoribonuclease or be incorporated by RdRp at a rate exceeding exoribonuclease excision velocity. In addition, the rational design of new potent exonucleases.
inhibitors in further research represents another strategy to overcome this deficiency of NAIs against SARS-CoV-2 RdRp.

Compared with NAIs, which are vulnerable to exonuclease cleavage, NNIs have the potential to be highly potent antivirals against SARS-CoV-2. As we reviewed previously, some natural compounds and their derivatives have been repurposed as strong NNIs against SARS-CoV-2 RdRp. Besides, alkaloids, plant polyphenols, including epigallocatechin-3-gallate (EGCG), silibinin, theaflavin, and fungal derivative cordycepin were also reported to establish strong and favorable binding interactions with the active site of SARS-CoV-2 RdRp by molecular dynamic simulation. It is recommended to test these natural products in the laboratory to determine their inhibitory efficacy, as such compounds may be promising alternative and complementary therapies for COVID-19 due to their diverse range of biological and therapeutic properties.

The continual emergence of mutations of SARS-CoV-2 is a cause of concern, as it may hinder the development of long-lasting effective RdRp inhibitors, in addition to promoting escape from vaccine-induced immune protection. Identifying potential hotspot residues contributing to antiviral resistance in SARS-CoV-2 is crucial for robust antiviral design and discovery. In addition, experience with other viral diseases suggests that combinations of inhibitors can provide a significant effect and prevent the evolution of drug-resistant virus mutants. Therefore, phytoc hemicals, in addition to other promising antivirals against SARS-CoV-2 RdRp, can be exploited for the development of a cocktail of inhibitors in the near future, which may have significant implications for alleviating the challenge of SARS-CoV-2 pandemic to the global public health threat.

Author contributions

XX, WX, and YC conceived this review. YC, WL, WF, LY wrote the initial draft of the review, WX and XX revised and edited the manuscript.

CRediT authorship contribution statement

Xiaoying Xu: Conceptualization, Methodology, Supervision, Writing – review & editing, Project administration, Funding acquisition. Xinyi Lu: Investigation, Data curation, Writing – original draft. Xinyu Lu: Investigation, Data curation, Writing – original draft. Wenxiu Fang: Conceptualization, Methodology, Supervision, Writing – review & editing, Project administration, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

This research was supported by the Zhejiang Provincial Natural Science Foundation of China (Grant No. LZQ20C050002), the Research Project of Zhejiang Chinese Medical University (2019R2909), National Natural Science Foundation of China (Grant No. 81973571), YUAN ZHI Outstanding Youth Research Foundation of ZCMI (2018) and YUAN ZHI Outstanding Doctor Research Foundation of ZCMI (2018). We also appreciate the support from the Public Research Platform of Academy of Chinese Medical Science, ZCMI.

References

[1] S. Muralidhar, S.V. Ambhi, S. Sekaran, U.M. Krishnan, The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2, Biochimie 179 (2020) 85–100.
Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-CoV-2 Infection, Pharmaceuticals (Basel) 15 (2021) 454.  

Y. Xie, W. Yin, Y. Wang, Z. Wang, Z. Wang, et al., Design and development of an oral remdesivir derivative VI116 against SARS-CoV-2, Cell Res. 31 (11) (2021) 1212–1214.  

Y. Li, B. Yang, Y. Quan, Z. Li, Advancement of Prodrug Approaches for Nucleic Acid Antiviral Agents, Top. Med. Chem. 21 (32) (2021) 2909–2927.  

H.J. Qian, Y. Wang, M.Q. Zhang, Y.C. Xie, Q.Q. Liu, L.Y. Liang, et al., Safety, tolerability, and pharmacokinetics of VI116, an oral nucleoside analogue against SARS-CoV-2 in Chinese healthy subjects, J. Med. Chem. 64 (4) (2021) 2040–2066.  

Y. Shen, J. Ai, N. Lin, H. Zhang, Y. Li, H. Wang, et al., An open, prospective cohort study of VI116 in Chinese participants infected with SARS-CoV-2: interim safety, Antivir. Med. Infect. 11 (5) (2021) 1518–1523.  

R.J. Mackman, H.J. Qian, M.M. Pernen, E. Murakami, C. Palmitost, G.G. Lee, et al., Prodrugs of a 1′-C4-N4-Aza-7,9-dideazaadenosine – Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV, J. Med. Chem. 64 (8) (2021) 5001–5017.  

A. Schafer, D.R. Martinez, J.J. Won, R.M. Megnak, F.R. Moreira, A.J. Brown, et al., Therapeutic treatment with an oral prodrug of the remdesivir parent nucleoside is protective against SARS-CoV-2 pathogenesis in mice, Sci. Transl. Med. 14 (643) (2022) eaax3410.  

R.M. Cox, J.D. Wolf, C.M. Lieber, J. Sourimant, M.J. Lin, D. Babusis, et al., Oral oxypurinol is efficacious against SARS-CoV-2 in ferrets, Nat. Commun. 12 (1) (2021) 6415.  

S.E. Good, J.H. Jung, X. Zhou, A. Mousa, P. La Colla, et al., AT-527, a Double-Prodrug of a Guanine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 and a Promising Oral Antiviral for Treatment of COVID-19, Antimicrob. Agents Chemother. 65 (4) (2021) e02479–20.  

C.B. Deumon, Current and future use of prodrug strategies in the treatment of hepatitis C virus infection, Antivir Chem Chemother. 26 (2018) 2040206618756430.  

J.Y. Han, K.H. Lee, S.Y. Nam, S. Ryu, D. Seong, et al., Treatment of hepatitis C virus (HCV) with a novel nucleoside analog, Antiviral Res. 112 (3) (2021) 1038–1043.  

X. Xu et al., A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase, Nat. Commun. 12 (5) (2021) 9441.  

K. Zandi, K. Musall, A. Oo, D. Cao, B. Liang, P. Hassandarvish, et al., Baicalein and baicalin in Chinese Volunteers, Clin. Drug Investig. 36 (9) (2016) 713–724.  

J.S. Mani, J.B. Johnson, J.C. Steel, D.A. Broszczak, P.M. Neilsen, K.B. Walsh, et al., Natural product-derived phytochemicals as potential agents against SARS-CoV-2, PJPII: A review of actives against coronavirus, Arch. Virol. 164 (2) (2019) 585–592.  

Y.J. Hu, L. Wu, N. Shao, Y. Gao, J. Wang, Y. Sun, et al., Anti-inflammatory activity of baicalein and baicalin in mice infected with SARS-CoV-2, in Chinese healthy subjects, Acta Pharmacol. Sin. 1 (2022) 2035–2045.  

H. Xiao, X. Xu, L. Du, H. Li, Z. Wang, et al., Lycorine and organ protection: Review of its potential effects and molecular mechanisms, Phytotherapy. 104 (2021) 152466.  

L. Shen, J. Niu, C. Wang, B. Huang, W. Niu, et al., High-Throughput Screening and Identifying Novel Spectrum Inhibitors of Coronavirus, J. Virol. 93 (12) (2019) e00223-19.  

J.S. Mani, J.B. Johnson, J.C. Steel, D.A. Broszczak, P.M. Neilsen, K.B. Walsh, et al., Natural product-derived phytochemicals as potential agents against SARS-CoV-2, PJPII: A review of actives against coronavirus, Arch. Virol. 164 (2) (2019) 585–592.  

Y.N. Zhang, Q.Y. Zhang, X.D. Li, J. Xiong, S.Q. Xiao, Z. Wang, et al., Gemicitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture, Emerg. Microbes Infect. 9 (5) (2020) 1170–1173.  

L.J. Yang, R.H. Chen, S. Hamdoun, P. Coghi, P.J.L. Ng, D.W. Zhang, et al., Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding, Antiviral Res. 87 (2021), 155591.  

J.H. Han, J. Sourimant, C. Baillard, G. Bonsignore, et al., Corilagin inhibits SARS-CoV-2 entry and activates AMPK signaling in a DDX3X-dependent manner, J. Virol. 95 (2021) e01270–20.  

B.S. Matada, R. Pattanashettar, N.G. Yernale, A comprehensive review on the anti-inflammatory activity of methylxanthines as natural immunomodulators, Ann. Pharmacother. 55 (5) (2021) 618–625.  

S. Huang, Y.e. Liu, Y. Zhang, R. Zhang, C. Zhu, L. Fan, et al., Baicalein inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res. 178 (2020), 104786.
[141] S.S.A. Karim, Q.A. Karim, Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic, Lancet (London, England) 398 (10317) (2021) 2126–2128.
[142] C. Kuhlmann, C.K. Mayer, M. Classen, T. Maponga, W.A. Burgers, R. Keeton, et al., Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose, Lancet (London, England) 399 (10325) (2022) 625–626.
[143] J. Zhao, S. Guo, D. Yi, Q. Li, L. Ma, Y. Zhang, et al., A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase, Antiviral Res. 190 (2021), 105078.
[144] O.M. Ogunyemi, G.A. Gyebi, A.A. Elfiky, S.O. Afolabi, O.B. Ogunro, A.P. Adegunloye, et al., Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an perspective, Antivir. Chem. Chemother. 28 (2020) 2040206620984076.
[145] A. Warowicka, R. Nawrot, A. Goździcka-Jozefiak, Antiviral activity of berberine, Arch. Virol. 165 (9) (2020) 1935–1945.
[146] Y.H. Jin, J. Lee, S. Jeon, S. Kim, J.S. Min, S. Kwon, Natural Polyphenols, 1,2,3,4,6-O-Pentagalloylgucose and Proanthocyanidins, as Broad-Spectrum Anticoronaviral Inhibitors Targeting Mpro and RdRp of SARS-CoV-2, Biomedicines 10 (5) (2022) 1170.